![](/img/cover-not-exists.png)
PDB8 WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?
O Pirk, KP Ratzmann, J Carels, P Bramlage, W KirchVolume:
7
Year:
2004
Language:
english
DOI:
10.1016/s1098-3015(10)65951-7
File:
PDF, 64 KB
english, 2004